Brief: Orchard Therapeutics Reports First Quarter 2023 Financial Results
15/05/2023 12:12
May 15 (Reuters) - Orchard Therapeutics PLC OT10y.F :
* ORCHARD THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS AND ANNOUNCES INITIATION OF ROLLING SUBMISSION FOR
BIOLOGICS LICENSE APPLICATION OF OTL-200 FOR METACHROMATIC
LEUKODYSTROPHY TO U.S. FDA
* ORCHARD THERAPEUTICS PLC - LIBMELDY REVENUE AND COMMERCIAL
PATIENTS TREATED EXPECTED TO GROW YEAR-OVER-YEAR IN 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 BIOLOGICS LICENSE
APPLICATION
(BLA) SUBMISSION COMPLETION ANTICIPATED IN MID-2023
* ORCHARD THERAPEUTICS PLC - CASH, CASH EQUIVALENTS AND
INVESTMENTS AS OF MARCH 31, 2023, WERE $146.3 MILLION
Source text for Eikon: ID:nGNX9RGbc4
Further company coverage: OT10y.F
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln